ClinicalTrials.gov record
Completed Phase 1Phase 2 Interventional

A Dose-Ranging Study of IV BNZ-1 in LGL Leukemia or Refractory CTCL

ClinicalTrials.gov ID: NCT03239392

Public ClinicalTrials.gov record NCT03239392. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced May 16, 2026, 2:18 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Dose-Ranging Study of Intravenous BNZ132-1-40 in Patients With Large Granular Lymphocyte Leukemia or Refractory Cutaneous T-Cell Lymphoma

Study identification

NCT ID
NCT03239392
Recruitment status
Completed
Study type
Interventional
Phase
Phase 1, Phase 2
Lead sponsor
Bioniz Therapeutics
Industry
Enrollment
50 participants

Conditions and interventions

Interventions

  • BNZ132-1-40 Drug

Drug

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Mar 31, 2018
Primary completion
Jun 29, 2020
Completion
Jun 29, 2020
Last update posted
May 24, 2021

2018 – 2020

United States locations

U.S. sites
4
U.S. states
4
U.S. cities
4
Facility City State ZIP Site status
City of Hope National Medical Center Duarte California 10101
Moffitt Cancer Center Tampa Florida 33612
The James Cancer Center, Ohio State University Columbus Ohio 43210
University of Virginia Cancer Center Charlottesville Virginia 22908

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT03239392, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted May 24, 2021 · Synced May 16, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT03239392 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →